A proposed measure would ban the use or consideration of China clinical trial data, reflecting renewed congressional concerns in Washington about data access, credibility, and competitive dynamics with China. While the measure is described as unlikely to be adopted, it signals how lawmakers may escalate pressure on how trial evidence is sourced and evaluated. For biotech companies with multinational development strategies, the potential ripple effect is uncertainty in evidence pathways—especially when trials are conducted through cross-border partnerships or regional clinical networks. The development also underscores how policy can move faster than trial timelines, forcing sponsors to evaluate contingency evidence plans ahead of regulatory reviews.